A lot of the research that ScHARR and HEDS conducts gains media and online attention. As with the last few quarterly periods we have taken a quick look at some the attention using Altmetrics to see what has been said about our work and how far and wide it has reached on social media channels.
HEDS work is regularly mentioned across the media, blogs, social media as well as getting cited in policy documents and Wikipedia entries. On the blog we often take a regular look as to the latest coverage our research receives using Altmetric data that scrapes the web for mentions of our work using DOIs and other unique identifiers. Since the end of June our work and collaborations have received an awful lot of attention. In total we received 3824 total mentions, of which 3,494 were Tweets, whilst we were featured or had our work linked to 101 news articles, 53 blogs and 105 Facebook Shares. HEDS work was also cited 36 times in policy documents (including translated and other versions) and appeared as six Wikipedia citations.
 |
| Tweets by country |
Work by Professor Allan Brennan and Colin Angus on impact of local alcohol licensing policies was cited in a The Conversation article and subsequent Yahoo News! story on binge drinkers back in August. Previous alcohol research by Brennan and Angus was also cited in a number of stories in the U.S. starting from Bloomberg and re-run in True Viral News, Arkansas Online, The Journal Gazette, The Keene Sentinel, The Bakersfield Californian and The Salt Lake Tribune. Our work was cited in news across 101 stories, in 69 unique outlets in 13 countries.
 |
| News coverage by country |
Looking at the policy documents, Professor Ben Van Hout’s work before he joined ScHARR is featured in a couple of publications. A paper published back in 1994 for Health Economics is cited in a NICE CDF Rapid Reconsideration on Cetuximab for the treatment of metastatic and/or recurrent squamous cell carcinoma of the head and neck (review of TA172)
Work involving Dr Andrew Booth from a paper published in PLoS Medicine is also cited in the NICE Clinical Guideline; Faltering Growth - recognition and management.